Skip to content

Nanoform significantly strengthens commercial organisation with Chief of Business Operations appointment


Nanoform significantly strengthens commercial organisation with Chief of Business Operations appointment

Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has appointed Dr Gonçalo Rebelo de Andrade as Chief of Business Operations. The newly created role will significantly strengthen Nanoform’s commercial organisation and continue its rapid growth through international sales.

The Chief of Business Operations position combines a commercial role with operational responsibility. Dr Andrade will work closely with the recently appointed Chief Commercial Officer, Christian Jones to manage operational activities for new projects and coordinate activities within the company to deliver exceptional service to clients. Nanoform’s proprietary particle engineering technology is responding to the demand for API nanoparticle generation. The new role will ensure delivery of nanonized particles to suit the needs of every client.

Dr Andrade has significant business development, management and intellectual property experience within the pharmaceutical and biotechnology fields. He has substantial knowledge of particle engineering through his previous role as Business Development Manager for the inhalation business at Hovione, a well-recognised particle engineering contract development and manufacturing company. He also developed his experience in building and growing businesses as Managing Director at Hovione Capital, a life Science focused venture capital company. Dr Andrade has served on several life science company boards and has extensive expertise in drug delivery in both US (Elan Pharmaceuticals) and EU based companies.

The appointment comes at an important time in the company’s evolution following considerable investment in its people and facilities. The employment of a Chief of Business Operations is a significant milestone for Nanoform, advancing its service provision to provide more drugs with a second chance at reaching the market.

Edward Hæggström, CEO of Nanoform said: “It gives me great pleasure to welcome Gonçalo to Nanoform. His background and experience in drug delivery will be a huge asset to the company. He will play a key role in the international expansion of the business, and I look forward to working with him to deliver this growth.”

Gonçalo Rebelo de Andrade added: “I am delighted to be joining Nanoform at this exciting time for the company. I can see significant potential for the technology and I am looking forward to working with the team to deliver breakout growth and position Nanoform as ‘the go-to experts’ for solving solubility and bioavailability challenges in the marketplace.”

Notes to the Editor

For further information, images and interview opportunities with Nanoform, please contact:
Pranika Sivakumar at Notch Communications
+44 (0) 161 457 7230

About Nanoform

Nanoform Finland Limited is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization services. The company’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESSᵀᴹ ) technology produces nanonized ‘designed-for-purpose’ API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization technology provides novel opportunities in diverse value enhancing drug delivery applications.

For more information please visit